{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.48","upperLimit":"100.00","value":"99.48"},{"groupId":"OG001","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"194"}],"units":"Participants"}],"title":"1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"97.52","upperLimit":"100.00","value":"98.96"},{"groupId":"OG001","lowerLimit":"95.94","upperLimit":"99.94","value":"97.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"190"}],"units":"Participants"}],"title":"2 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.78","upperLimit":"99.94","value":"97.86"},{"groupId":"OG001","lowerLimit":"93.74","upperLimit":"99.01","value":"96.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"185"}],"units":"Participants"}],"title":"3 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.78","upperLimit":"99.94","value":"97.86"},{"groupId":"OG001","lowerLimit":"91.68","upperLimit":"97.94","value":"94.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"title":"4 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.26","upperLimit":"98.94","value":"96.10"},{"groupId":"OG001","lowerLimit":"90.33","upperLimit":"97.17","value":"93.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"177"}],"units":"Participants"}],"title":"5 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"The Kaplan-Meier method was used to estimate the percentage of participants who were event-free at landmark timepoints. Overall survival (OS) was defined as the time from enrollment to death from any cause. Participants who were alive or lost to follow-up were censored at their last known date in the study. Participants with no post-baseline assessments were censored at the date of enrollment plus 1 day.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m\\^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m\\^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m\\^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams \\[mg\\] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram \\[mg/kg\\] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.","id":"OG000","title":"Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab"},{"description":"Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m\\^2 intravenously (IV) q3w, epirubicin 100mg/m\\^2 IV q3w, and cyclophosphamide 600mg/m\\^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m\\^2 in Cycle 5, then 100mg/m\\^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.","id":"OG001","title":"Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab"}],"paramType":"NUMBER","populationDescription":"ITT population: included all participants who were enrolled regardless of whether they received any study treatment, grouped according to the arm to which a participant was enrolled. The number analyzed per timepoint represents the number of participants remaining at risk at that timepoint.","reportingStatus":"POSTED","timeFrame":"At 1, 2, 3, 4, and 5 years","title":"Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1 to 5 Years","type":"SECONDARY","unitOfMeasure":"Estimate of percentage of participants"}